Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 6/20 | 0.47 |
| ▸ | ABHD6 | Q9BV23 | 10/20 | 0.43 |
| ▸ | MGLL | Q99685 | 5/20 | 0.37 |
| ▸ | LOX | P28300 | 1/20 | 0.32 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25297104 | 0.85 | LOXL2 (0.46) | LOXL2ABHD6MGLL | |
| SCHEMBL29497063 | 0.85 | LOXL2 (0.46) | LOXL2ABHD6MGLL | |
| SCHEMBL31308012 | 0.83 | LOXL2 (0.39) | LOXL2ABHD6IDH1 | |
| SCHEMBL30553220 | 0.81 | LOXL2 (0.40) | LOXL2ABHD6MGLLDGAT2 | |
| SCHEMBL25324473 | 0.81 | LOXL2 (0.40) | LOXL2ABHD6MGLLDGAT2 | |
| SCHEMBL25252074 | 0.80 | LOXL2 (0.43) | LOXL2ABHD6MGLL | |
| SCHEMBL30700008 | 0.78 | LOXL2 (0.40) | LOXL2ABHD6MGLLDGAT2 | |
| SCHEMBL30699921 | 0.78 | LOXL2 (0.40) | LOXL2ABHD6MGLLDGAT2 | |
| SCHEMBL25301249 | 0.77 | LOXL2 (0.35) | LOXL2IDH1 | |
| SCHEMBL25296127 | 0.77 | LOXL2 (0.39) | LOXL2ABHD6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11981661-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2024-05-14 | — | — | US | disclosed |
| EP-4208456-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2023-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11981661-B2 | Heterocyclic compounds | CBR3, BRIX1, CCNY | LOXL2 232/4885ABHD6 2620/4885MGLL 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.